Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of anti-PDCD4 (Programmed Cell Death 4) antibody in preparation of detection reagent for predicting personalized medicine sensitivity of paclitaxel or derivative drug of paclitaxel

A detection kit, paclitaxel technology, applied in the direction of biological material analysis, measuring devices, instruments, etc., can solve the problems of unclear specific inhibitory targets, and achieve simple and easy detection methods, good reproducibility of results, and significant economic benefits and the effect of social benefits

Inactive Publication Date: 2014-11-19
HARBIN MEDICAL UNIVERSITY
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, PDCD4 is likely to be a translational repressor with specific targets, but its full set of specific repressive targets is unknown

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of anti-PDCD4 (Programmed Cell Death 4) antibody in preparation of detection reagent for predicting personalized medicine sensitivity of paclitaxel or derivative drug of paclitaxel
  • Application of anti-PDCD4 (Programmed Cell Death 4) antibody in preparation of detection reagent for predicting personalized medicine sensitivity of paclitaxel or derivative drug of paclitaxel
  • Application of anti-PDCD4 (Programmed Cell Death 4) antibody in preparation of detection reagent for predicting personalized medicine sensitivity of paclitaxel or derivative drug of paclitaxel

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Embodiment 1: the relationship between the expression level of tumor suppressor PDCD4 and paclitaxel drug sensitivity

[0043] Cell lines: Human ovarian cancer cell line UACC-1598 was donated by Dr. Guan Xinyuan, Department of Clinical Oncology, University of Hong Kong; human cervical cancer cell line HeLa and human osteosarcoma cell line U2-OS were purchased from Shanghai Cell Bank, Chinese Academy of Sciences; human colon cancer cell line HT -29 was purchased from the American Type Culture Collection (ATCC). at 37°C, 5% CO 2 Under these conditions, UACC-1598 and HeLa cells were cultured in RPMI-1640 medium containing 10% fetal bovine serum; HT-29 cells were cultured in DMEM high-glucose medium containing 15% fetal bovine serum; U2-OS cells were cultured in Cultured in MDEM medium containing 10% fetal bovine serum.

[0044] The main biochemical reagents required:

[0045] Opti-MEM medium (Sigma company)

[0046] Polyethylenimine transfection reagent (Polysciences) ...

Embodiment 2

[0100] Example 2: Detection of PDCD4 protein expression level in clinical lung cancer tissue by immunoblotting method and its guiding significance to paclitaxel individualized drug use

[0101] 1. Lung cancer tissue acquisition: Frozen samples of lung cancer and paracancerous tissues from the Department of Thoracic Surgery, Affiliated Hospital of Harbin Medical University in 2010 were selected, including 77 lung cancer tissues and paracancerous tissues, including 56 males and 21 females. All the collected tissues were diagnosed by experienced pathologists, and no lymphatic metastasis or metastasis of adjacent tissues and organs was found. The age of lung cancer patients in this group ranged from 36 to 75 years old, with an average age of 60 years; there were 26 cases of adenocarcinoma, 42 cases of squamous cell carcinoma and 9 cases of others. Seventy-seven patients with lung cancer received paclitaxel combined with adjuvant chemotherapy. The tissue samples used in this exper...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of an anti-PDCD4 (Programmed Cell Death 4) antibody in preparation of a detection reagent for predicting personalized medicine sensitivity of paclitaxel or a derivative drug of paclitaxel. The variation of protein abundance of whole cells in tumor cells treated by paclitaxel is analyzed by using a quantitative proteomics technology, the results shows that paclitaxel reduces the expression level of PDCD4 and the sensitivity of the tumor cells to paclitaxel is in positive correlation with the expression level of PDCD4 in cells. PDCD4 in the tumor cells is subject to gene silencing or overexpression and the result further proves that the sensitivity of the cells to paclitaxel is in positive correlation with the expression level of PDCD4 in the cells. Meanwhile, researches on survival prognosis of clinical lung cancer patients shows that under the same paclitaxel combined adjuvant chemotherapy, the survival prognosis of patients with low expression level of PDCD4 is poor and the survival time of patients with high expression level of PDCD4 is long. Based on the research results, the invention provides a reference index and a detection and application method for guiding personalized medicine of paclitaxel or the derivative drug (such as docetaxel) of the paclitaxel.

Description

technical field [0001] The invention relates to a reference index for guiding the drug application of paclitaxel, in particular to the application of an antibody against tumor suppressor PDCD4 in guiding the individualized medication of paclitaxel or its derivative drugs, and the invention belongs to the field of biotechnology. Background technique [0002] Paclitaxel (PTX) is a new type of antineoplastic drug, which promotes the polymerization of tubulin and inhibits its depolymerization, so that cells are arrested in mitosis, thereby inhibiting cell proliferation (Jordan, MA et al, Cancer Research ,1996). Because of its unique anti-cancer mechanism acting on the microtubule system of cells, it has been used in the clinical treatment of breast cancer, ovarian cancer, lung cancer, colorectal cancer, bladder cancer, etc. Paclitaxel can also enhance the sensitivity of radiotherapy drugs, and is often used in combination with radiotherapy. [0003] Lung cancer is one of the m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/574
CPCG01N33/57423G01N2800/7028
Inventor 周春水张海员刘佳玮傅松滨白静徐晖孙慧莹范芳芳李亦兰刘宝刚刘通高民戴绍春宁雪莲孙悦
Owner HARBIN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com